The United States represents a significant market for Epalrestat, driven by the rising prevalence of diabetes, increasing focus on managing diabetic complications, and continuous advancements in chronic disease care. Growing awareness of diabetic neuropathy, expanding diabetes management programs, and strong investments in pharmaceutical research are supporting the demand for effective...